Uni Eropa - Italia - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - neoplasie prostatiche - terapia endocrina - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - dutasteridum, tamsulosini hydrochloridum - capsule - dutasteridum 0.5 mg, tamsulosini hydrochloridum 0.4 mg corresp. tamsulosinum 0.367 mg, dutasterid-weichkapsel innerhalb der hartkapsel: glyceroli mono/dioctanoas/decanoas, e 321, gelatina, glycerolum, e 171, e 172, aqua purificata, triglycerida media, lecithinum ex soja, tamsulosin-pellets in hartkapsel: cellulosum microcristallinum, acidi methacrylici et ethylis acrylatis polymerisati 1:1 dispersio 30 per centum cum polysorbatum 80 et natrii laurilsulfas, talcum, triethylis citras, aqua purificata, kapselhülle: carrageenanum, kalii chloridum, aqua purificata, hypromellosum, cera carnauba, maydis amylum, e 110 0.04-0.08 mg, e 171, e 172, drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula corresp. natrium 245 µg. - iperplasia prostatica benigna - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - dutasteridum, tamsulosinum - capsule - dutasteridum 0.5 mg, tamsulosini hydrochloridum 0.4 mg corresp. tamsulosinum 0.367 mg, propylenglycoli monooctanoas corresp. propylenglycolum 112.65 mg, e 321, gelatina, glycerolum, e 171, acidi methacrylici et ethylis acrylatis polymerisatum 1:1 cum polysorbatum 80 et natrii laurilsulfas corresp. natrium 0.09 mg, cellulosum microcristallinum, dibutylis sebacas, silica colloidalis hydrica, calcii stearas, kapselhülle: gelatina, e 171, e 172 (nigrum), e 172 (rubrum), e 172 (flavum), drucktinte: propylenglycolum, lacca, e 172 (nigrum), ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - iperplasia prostatica benigna - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - dutasteridum, tamsulosini hydrochloridum - capsule - dutasteridum 0.5 mg, tamsulosini hydrochloridum 0,4 mg corrisp. tamsulosinum 0.367 mg, antiox.: e 321, excipiens per la capsula. - iperplasia prostatica benigna - synthetika

Italia - Italia - AIFA (Agenzia Italiana del Farmaco)

farma group s.r.l. - piracetam - piracetam

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dutasteridum, tamsulosinum - capsule - dutasteridum 0.5 mg, tamsulosini hydrochloridum 0.4 mg corresp. tamsulosinum 0.367 mg, dutasterid-weichkapsel innerhalb der hartkapsel: propylenglycoli dicaprylocapras 299.46 mg corresp. propylenglycolum 112.8 mg, e 321, gelatina, e 171, glycerolum, triglycerida media, lecithinum ex soja q.s., tamsulosin-pellets in hartkapsel: cellulosum microcristallinum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1 cum polysorbatum 80 et natrii laurilsulfas corresp. natrium 0.09 mg, dibutylis sebacas, silica colloidalis hydrica, calcii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 171, e 172 (flavum), gelatina, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - iperplasia prostatica benigna - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - dutasteridum, tamsulosini hydrochloridum - capsule - dutasteridum 0.5 mg, tamsulosini hydrochloridum 0.4 mg corresp. tamsulosinum 0.367 mg, dutasterid-weichkapsel innerhalb der hartkapsel: glyceroli monocaprylocapras, e 321, gelatina, glycerolum 64.2 mg, aqua purificata, e 171, e 172 (flavum), triglycerida media, lecithinum ex soja, tamsulosin-pellets in hartkapsel: cellulosum microcristallinum, magnesii stearas, acidi methacrylici et ethylis acrylatis polymerisati 1:1 dispersio 30 per centum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii hydroxidum corresp. natrium 0.05 mg, triacetinum, e 171, talcum, kapselhülle: hypromellosum, kalii chloridum, carrageenanum, e 171, e 110 0.06 mg, e 172 (rubrum), aqua purificata, pro capsula. - iperplasia prostatica benigna - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

xiromed sa - dutasteridum, tamsulosini hydrochloridum - capsule rigide - dutasteridum 0.5 mg, tamsulosini hydrochloridum 0.4 mg corresp. tamsulosinum 0.367 mg, dutasterid-weichkapsel innerhalb der hartkapsel: propylenglycoli monooctanoas corresp. propylenglycolum 112.65 mg, e 321, gelatina, e 171, glycerolum, triglycerida media, lecithinum ex soja, tamsulosin-pellets in hartkapsel: acidi methacrylici et ethylis acrylatis polymerisatum 1:1 cum polysorbatum 80 et natrii laurilsulfas corresp. natrium 0.09 mg, cellulosum microcristallinum, dibutylis sebacas, silica colloidalis hydrica, calcii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 171, e 172 (flavum), gelatina, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - iperplasia prostatica benigna - synthetika

Italia - Italia - AIFA (Agenzia Italiana del Farmaco)

spa societa' prodotti antibiotici s.p.a. - metronidazolo - metronidazolo

Italia - Italia - AIFA (Agenzia Italiana del Farmaco)

pfizer italia s.r.l. - gemfibrozil - gemfibrozil